Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal hUC-MSC-sEV-001 in ALS
NCT06598202Phase 2Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of exosomes derived from human umbilical cord blood mesenchymal stem cells in amyotrophic lateral sclerosis (ALS), sponsored by Xuanwu Hospital. Started Dec 2024; status: recruiting.
02
Drugs
exosomes derived from human umbilical cord blood mesenchymal stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06598202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598202.